GO:0006915 apoptotic process: Genes & Methods

The apoptotic process (GO:0006915) is a programmed cell death process that begins when a cell receives an internal signal, such as DNA damage, or an external signal, such as an extracellular death ligand, and proceeds through a series of biochemical events that culminate in an execution phase. This execution phase is the last step of an apoptotic process and is typically characterized by rounding-up of the cell, retraction of pseudopodes, reduction of cellular volume (pyknosis), chromatin condensation, nuclear fragmentation (karyorrhexis), plasma membrane blebbing, and fragmentation of the cell into apoptotic bodies; when the execution phase is completed, the cell has died. Apoptosis is distinct from other forms of cell death in its genetically encoded, signal-dependent nature and its characteristic morphology. Researchers study apoptotic process because it is a central mechanism in development, tissue homeostasis, and disease. Defective or excessive apoptosis underlies cancer, autoimmune conditions, cystic fibrosis, HIV pathogenesis, and ovarian follicle atresia. The process is also a therapeutic target: re-establishing a normal apoptotic process has been proposed as a therapeutic approach in B-cell chronic lymphocytic leukemia, and exploiting the apoptotic process has been explored for management of HIV. At the molecular level, apoptosis is executed through caspase-dependent signaling cascades and mitochondrial events. Mitochondrial membrane permeabilization is a key step in the intrinsic pathway, releasing pro-apoptotic factors that activate downstream executioners. The extrinsic pathway is triggered by death ligands such as Fas ligand, which engage cell-surface receptors and initiate initiator caspase activity. Because these pathways are genetically tractable, apoptotic process is a frequent subject of CRISPR-based functional genomics.

In the Gene Ontology, apoptotic process (GO:0006915) is defined as a programmed cell death process that begins when a cell receives an internal signal (e.g., DNA damage) or external signal (e.g., an extracellular death ligand), and proceeds through a series of biochemical events (the signaling pathway phase) which trigger an execution phase. The execution phase is the last step of an apoptotic process and is typically characterized by rounding-up of the cell, retraction of pseudopodes, reduction of cellular volume (pyknosis), chromatin condensation, nuclear fragmentation (karyorrhexis), plasma membrane blebbing, and fragmentation of the cell into apoptotic bodies; when the execution phase is completed, the cell has died. The term is a biological_process and includes synonyms such as apoptosis, apoptotic cell death, apoptotic programmed cell death, caspase-dependent programmed cell death, cell suicide, and type I programmed cell death.

Apoptotic process is important because it is the principal genetically programmed mechanism by which multicellular organisms eliminate unwanted, damaged, or dangerous cells, and its dysregulation is causally linked to major human diseases. In cancer, failure to execute apoptosis allows malignant cells to survive and resist therapy, making re-establishment of a normal apoptotic process a rational therapeutic strategy. In HIV infection, modulating the apoptotic process has been explored as a management approach. In cystic fibrosis, apoptotic process in disease cells has been studied as a contributing mechanism. In reproductive biology, ovarian follicle atresia is a hormonally controlled apoptotic process. Finally, efficient removal of apoptotic cells is required to prevent secondary necrosis and inflammation, and this clearance process is itself an active, regulated event.

The following genes and proteins are central to apoptotic process signaling, execution, and clearance, and are frequently studied using CRISPR models.

Apoptotic process is tightly regulated at multiple levels. The intrinsic pathway is controlled by the balance of pro-apoptotic and anti-apoptotic BCL2-family proteins, which govern mitochondrial membrane permeabilization. The extrinsic pathway is regulated by death ligand availability and receptor engagement, as exemplified by Fas ligand-induced apoptosis. Caspase activity is further restrained by inhibitor-of-apoptosis proteins, and the execution phase is only completed when these brakes are overcome. In disease contexts, therapeutic strategies aim to re-establish a normal apoptotic process, for example in B-cell chronic lymphocytic leukemia. Clearance of apoptotic cells is also regulated, and defects in this clearance can shift the process toward inflammation.

Failure to execute apoptosis allows malignant cells to survive and resist treatment, and re-establishing a normal apoptotic process has been proposed as a therapeutic approach in B-cell chronic lymphocytic leukemia. Anti-apoptotic regulators such as BCL2 are therefore key nodes for intervention.

Apoptotic process in cystic fibrosis cells has been characterized, linking dysregulated cell death to disease pathology. This provides a rationale for studying apoptotic signaling in cystic fibrosis models.

Exploiting the apoptotic process has been explored for management of HIV, reflecting the role of apoptosis in viral pathogenesis and immune cell depletion.

Ovarian follicle atresia is a hormonally controlled apoptotic process, demonstrating the role of apoptosis in reproductive physiology.

Because the execution phase of apoptotic process is defined by characteristic morphology, including cell rounding, pyknosis, chromatin condensation, karyorrhexis, membrane blebbing, and apoptotic bodies, imaging-based assays are essential to confirm apoptosis.

Caspase-dependent programmed cell death can be monitored through caspase activity assays, while mitochondrial membrane permeabilization assays report on the intrinsic pathway.

Fas ligand-induced apoptosis provides a tractable system to measure extrinsic pathway activation and receptor-proximal signaling events.

Apoptotic cell removal can be quantified using phagocytosis assays that measure recognition and engulfment of apoptotic bodies by phagocytes.

Researchers studying apoptotic process-related genes often need to determine whether a candidate gene is causally involved in cell death, whether a specific variant alters apoptotic sensitivity, and how the gene behaves in a disease background. EDITGENE provides the CRISPR tools and bioinformatics support required to answer these questions with publication-grade rigor.

Apoptotic process (GO:0006915) is a foundational biological process that removes cells through a genetically encoded signaling and execution program defined by characteristic morphology. Its dysregulation is central to cancer, cystic fibrosis, HIV pathogenesis, and reproductive biology, making it a high-value target for mechanistic and therapeutic research. CRISPR-based knockout, point-mutation, knock-in, overexpression, and library screening approaches provide the causal evidence needed to translate apoptotic process biology into clinical insight.